Roche announced Wednesday that it has obtained CE marking for a companion diagnostic test to identify patients with metastatic breast cancer with low HER2 expression eligible for Enhertu, AstraZeneca's new anticancer drug.

The 'Ventana HER2 (4B5)' test now includes an algorithm targeting HER2 levels to help physicians establish targeted therapy with Enhertu, an antibody-drug conjugate that specifically targets HER2.

According to Roche, nearly half of patients with metastatic breast cancer express low levels of HER2, a protein that promotes the growth of cancer cells.

Breast cancer recently overtook lung cancer as the most diagnosed cancer in the world, with around 2.3 million new cases worldwide each year.

More than 685,000 deaths annually are attributed to the disease.

Copyright (c) 2024 All rights reserved.